Page last updated: 2024-12-04

2-fluorohexadecanoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-fluorohexadecanoic acid: inhibits sphingosine base formation & accumulates in membrane lipids of cultured mammalian cells [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1560
CHEMBL ID1373832
CHEBI ID94978
SCHEMBL ID337296
MeSH IDM0120615

Synonyms (54)

Synonym
CBIOL_002000
BIO1_000775
BIO1_000286
BIO1_001264
BIO2_000135
BIO2_000615
BSPBIO_001415
IDI1_033885
nsc158288
nsc-158288
16518-94-8
2-fluoro-hexadecanoic acid
2-fluoropalmitic acid
hexadecanoic acid, 2-fluoro-
LMFA01090041
NCGC00161355-01
NCGC00161355-02
KBIO3_000270
KBIOGR_000135
KBIO3_000269
KBIOSS_000135
KBIO2_002703
KBIO2_005271
KBIO2_000135
NCGC00161355-03
HMS1989G17
BML3-C06
HMS1361G17
HMS1791G17
2-fluorohexadecanoic acid
dl-alpha-fluoropalmitic acid
nsc 158288
BRD-A94451536-001-01-0
SCHEMBL337296
AKOS022181448
2-fluoro palmitic acid
JGRIJJOLCNCSNX-UHFFFAOYSA-N
CHEMBL1373832
HMS3649L15
HMS3402G17
89270-22-4
CHEBI:94978
fluoropalmitic acid
Q27166740
2-fluoropalmiticacid
SR-01000946674-1
sr-01000946674
MS-23907
STARBLD0019658
CS-0066744
2-fluoropalmitic acid activity: acyl-coa synthase inhibitor
HY-117651
PD020524
DTXSID001347659
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
long-chain fatty acidA fatty acid with a chain length ranging from C13 to C22.
fluoro fatty acidAny halo fatty acid containing at least one fluoro substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Microtubule-associated protein tauHomo sapiens (human)Potency0.89130.180013.557439.8107AID1468
regulator of G-protein signaling 4Homo sapiens (human)Potency0.10620.531815.435837.6858AID504845
glucocerebrosidaseHomo sapiens (human)Potency5.62340.01268.156944.6684AID2101
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (22.22)18.7374
1990's1 (11.11)18.2507
2000's1 (11.11)29.6817
2010's2 (22.22)24.3611
2020's3 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.49 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.79 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]